Gln27 arrow right Glu beta 2-Adrenergic Receptor Polymorphism in Heart Failure Patients: Differential Clinical and Oxidative Response to Carvedilol

We investigated the clinical response of chronic heart failure patients with beta 2-adrenergic receptor Gln27 arrow right Glu polymorphism treated for 6 months with carvedilol, a alpha / beta -antagonist with antioxidant properties. The 6-min. walk test, the left ventricular ejection fraction, heart...

Full description

Saved in:
Bibliographic Details
Published in:Basic & clinical pharmacology & toxicology 2009-05, Vol.104 (5), p.374-378
Main Authors: Troncoso, Rodrigo, Moraga, Francisco, Chiong, Mario, Roldan, Juan, Bravo, Roberto, Valenzuela, Rodrigo, Diaz-Araya, Guillermo, del Campo, Andrea, Sanhueza, Carlos, Rodriguez, Andrea, Vukasovic, Jose Luis, Mellado, Rosemarie, Greig, Douglas, Castro, Pablo F, Lavandero, Sergio
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 378
container_issue 5
container_start_page 374
container_title Basic & clinical pharmacology & toxicology
container_volume 104
creator Troncoso, Rodrigo
Moraga, Francisco
Chiong, Mario
Roldan, Juan
Bravo, Roberto
Valenzuela, Rodrigo
Diaz-Araya, Guillermo
del Campo, Andrea
Sanhueza, Carlos
Rodriguez, Andrea
Vukasovic, Jose Luis
Mellado, Rosemarie
Greig, Douglas
Castro, Pablo F
Lavandero, Sergio
description We investigated the clinical response of chronic heart failure patients with beta 2-adrenergic receptor Gln27 arrow right Glu polymorphism treated for 6 months with carvedilol, a alpha / beta -antagonist with antioxidant properties. The 6-min. walk test, the left ventricular ejection fraction, heart rate, plasma norepinephrine and malondialdehyde, a stress oxidative marker, concentrations were evaluated at baseline and after treatment for 6 months with carvedilol in 33 stable chronic heart failure patients with the Gln27 arrow right Glu beta 2-adrenergic receptor polymorphism. Carvedilol significantly increased the left ventricular ejection fraction, while decreasing the heart rate and malondialdehyde plasma concentrations in chronic heart failure patients with the Glu27 beta 2-adrenergic receptor allele. There were however, no significant changes in patients with the Gln27 beta 2-adrenergic receptor variant.
doi_str_mv 10.1111/j.1742-7843.2008.00370.x
format article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_20583303</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20583303</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_205833033</originalsourceid><addsrcrecordid>eNqNjM1OwzAQhC0EEuXnHfbELcaxUyXihgJtb60Q98okm3arjR1sp5Tn4IXJAfXMXGak-WaEgFzJfNLjQeZlobOyKozUSlVSKVMqeboQs3Nxec5mfi1uYjwopcsiVzPxs2SnS7Ah-C8ItNsnWPIIH5gs6Oy5Degw7KiBN2xwSD7AxvN378Owp9gDOVihDQkWlngMCBubCF2KT_BCXYfTPJFlqJkcNVOwroX1idoJO-J0GgfvIkLyUNtwxJbY85246ixHvP_zW_GweH2vV9kQ_OeIMW17ig0yW4d-jFut5pUxyph_g7_YG2JL</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20583303</pqid></control><display><type>article</type><title>Gln27 arrow right Glu beta 2-Adrenergic Receptor Polymorphism in Heart Failure Patients: Differential Clinical and Oxidative Response to Carvedilol</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Troncoso, Rodrigo ; Moraga, Francisco ; Chiong, Mario ; Roldan, Juan ; Bravo, Roberto ; Valenzuela, Rodrigo ; Diaz-Araya, Guillermo ; del Campo, Andrea ; Sanhueza, Carlos ; Rodriguez, Andrea ; Vukasovic, Jose Luis ; Mellado, Rosemarie ; Greig, Douglas ; Castro, Pablo F ; Lavandero, Sergio</creator><creatorcontrib>Troncoso, Rodrigo ; Moraga, Francisco ; Chiong, Mario ; Roldan, Juan ; Bravo, Roberto ; Valenzuela, Rodrigo ; Diaz-Araya, Guillermo ; del Campo, Andrea ; Sanhueza, Carlos ; Rodriguez, Andrea ; Vukasovic, Jose Luis ; Mellado, Rosemarie ; Greig, Douglas ; Castro, Pablo F ; Lavandero, Sergio</creatorcontrib><description>We investigated the clinical response of chronic heart failure patients with beta 2-adrenergic receptor Gln27 arrow right Glu polymorphism treated for 6 months with carvedilol, a alpha / beta -antagonist with antioxidant properties. The 6-min. walk test, the left ventricular ejection fraction, heart rate, plasma norepinephrine and malondialdehyde, a stress oxidative marker, concentrations were evaluated at baseline and after treatment for 6 months with carvedilol in 33 stable chronic heart failure patients with the Gln27 arrow right Glu beta 2-adrenergic receptor polymorphism. Carvedilol significantly increased the left ventricular ejection fraction, while decreasing the heart rate and malondialdehyde plasma concentrations in chronic heart failure patients with the Glu27 beta 2-adrenergic receptor allele. There were however, no significant changes in patients with the Gln27 beta 2-adrenergic receptor variant.</description><identifier>ISSN: 1742-7835</identifier><identifier>EISSN: 1742-7843</identifier><identifier>DOI: 10.1111/j.1742-7843.2008.00370.x</identifier><language>eng</language><ispartof>Basic &amp; clinical pharmacology &amp; toxicology, 2009-05, Vol.104 (5), p.374-378</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Troncoso, Rodrigo</creatorcontrib><creatorcontrib>Moraga, Francisco</creatorcontrib><creatorcontrib>Chiong, Mario</creatorcontrib><creatorcontrib>Roldan, Juan</creatorcontrib><creatorcontrib>Bravo, Roberto</creatorcontrib><creatorcontrib>Valenzuela, Rodrigo</creatorcontrib><creatorcontrib>Diaz-Araya, Guillermo</creatorcontrib><creatorcontrib>del Campo, Andrea</creatorcontrib><creatorcontrib>Sanhueza, Carlos</creatorcontrib><creatorcontrib>Rodriguez, Andrea</creatorcontrib><creatorcontrib>Vukasovic, Jose Luis</creatorcontrib><creatorcontrib>Mellado, Rosemarie</creatorcontrib><creatorcontrib>Greig, Douglas</creatorcontrib><creatorcontrib>Castro, Pablo F</creatorcontrib><creatorcontrib>Lavandero, Sergio</creatorcontrib><title>Gln27 arrow right Glu beta 2-Adrenergic Receptor Polymorphism in Heart Failure Patients: Differential Clinical and Oxidative Response to Carvedilol</title><title>Basic &amp; clinical pharmacology &amp; toxicology</title><description>We investigated the clinical response of chronic heart failure patients with beta 2-adrenergic receptor Gln27 arrow right Glu polymorphism treated for 6 months with carvedilol, a alpha / beta -antagonist with antioxidant properties. The 6-min. walk test, the left ventricular ejection fraction, heart rate, plasma norepinephrine and malondialdehyde, a stress oxidative marker, concentrations were evaluated at baseline and after treatment for 6 months with carvedilol in 33 stable chronic heart failure patients with the Gln27 arrow right Glu beta 2-adrenergic receptor polymorphism. Carvedilol significantly increased the left ventricular ejection fraction, while decreasing the heart rate and malondialdehyde plasma concentrations in chronic heart failure patients with the Glu27 beta 2-adrenergic receptor allele. There were however, no significant changes in patients with the Gln27 beta 2-adrenergic receptor variant.</description><issn>1742-7835</issn><issn>1742-7843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNqNjM1OwzAQhC0EEuXnHfbELcaxUyXihgJtb60Q98okm3arjR1sp5Tn4IXJAfXMXGak-WaEgFzJfNLjQeZlobOyKozUSlVSKVMqeboQs3Nxec5mfi1uYjwopcsiVzPxs2SnS7Ah-C8ItNsnWPIIH5gs6Oy5Degw7KiBN2xwSD7AxvN378Owp9gDOVihDQkWlngMCBubCF2KT_BCXYfTPJFlqJkcNVOwroX1idoJO-J0GgfvIkLyUNtwxJbY85246ixHvP_zW_GweH2vV9kQ_OeIMW17ig0yW4d-jFut5pUxyph_g7_YG2JL</recordid><startdate>20090501</startdate><enddate>20090501</enddate><creator>Troncoso, Rodrigo</creator><creator>Moraga, Francisco</creator><creator>Chiong, Mario</creator><creator>Roldan, Juan</creator><creator>Bravo, Roberto</creator><creator>Valenzuela, Rodrigo</creator><creator>Diaz-Araya, Guillermo</creator><creator>del Campo, Andrea</creator><creator>Sanhueza, Carlos</creator><creator>Rodriguez, Andrea</creator><creator>Vukasovic, Jose Luis</creator><creator>Mellado, Rosemarie</creator><creator>Greig, Douglas</creator><creator>Castro, Pablo F</creator><creator>Lavandero, Sergio</creator><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>20090501</creationdate><title>Gln27 arrow right Glu beta 2-Adrenergic Receptor Polymorphism in Heart Failure Patients: Differential Clinical and Oxidative Response to Carvedilol</title><author>Troncoso, Rodrigo ; Moraga, Francisco ; Chiong, Mario ; Roldan, Juan ; Bravo, Roberto ; Valenzuela, Rodrigo ; Diaz-Araya, Guillermo ; del Campo, Andrea ; Sanhueza, Carlos ; Rodriguez, Andrea ; Vukasovic, Jose Luis ; Mellado, Rosemarie ; Greig, Douglas ; Castro, Pablo F ; Lavandero, Sergio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_205833033</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Troncoso, Rodrigo</creatorcontrib><creatorcontrib>Moraga, Francisco</creatorcontrib><creatorcontrib>Chiong, Mario</creatorcontrib><creatorcontrib>Roldan, Juan</creatorcontrib><creatorcontrib>Bravo, Roberto</creatorcontrib><creatorcontrib>Valenzuela, Rodrigo</creatorcontrib><creatorcontrib>Diaz-Araya, Guillermo</creatorcontrib><creatorcontrib>del Campo, Andrea</creatorcontrib><creatorcontrib>Sanhueza, Carlos</creatorcontrib><creatorcontrib>Rodriguez, Andrea</creatorcontrib><creatorcontrib>Vukasovic, Jose Luis</creatorcontrib><creatorcontrib>Mellado, Rosemarie</creatorcontrib><creatorcontrib>Greig, Douglas</creatorcontrib><creatorcontrib>Castro, Pablo F</creatorcontrib><creatorcontrib>Lavandero, Sergio</creatorcontrib><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Basic &amp; clinical pharmacology &amp; toxicology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Troncoso, Rodrigo</au><au>Moraga, Francisco</au><au>Chiong, Mario</au><au>Roldan, Juan</au><au>Bravo, Roberto</au><au>Valenzuela, Rodrigo</au><au>Diaz-Araya, Guillermo</au><au>del Campo, Andrea</au><au>Sanhueza, Carlos</au><au>Rodriguez, Andrea</au><au>Vukasovic, Jose Luis</au><au>Mellado, Rosemarie</au><au>Greig, Douglas</au><au>Castro, Pablo F</au><au>Lavandero, Sergio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gln27 arrow right Glu beta 2-Adrenergic Receptor Polymorphism in Heart Failure Patients: Differential Clinical and Oxidative Response to Carvedilol</atitle><jtitle>Basic &amp; clinical pharmacology &amp; toxicology</jtitle><date>2009-05-01</date><risdate>2009</risdate><volume>104</volume><issue>5</issue><spage>374</spage><epage>378</epage><pages>374-378</pages><issn>1742-7835</issn><eissn>1742-7843</eissn><abstract>We investigated the clinical response of chronic heart failure patients with beta 2-adrenergic receptor Gln27 arrow right Glu polymorphism treated for 6 months with carvedilol, a alpha / beta -antagonist with antioxidant properties. The 6-min. walk test, the left ventricular ejection fraction, heart rate, plasma norepinephrine and malondialdehyde, a stress oxidative marker, concentrations were evaluated at baseline and after treatment for 6 months with carvedilol in 33 stable chronic heart failure patients with the Gln27 arrow right Glu beta 2-adrenergic receptor polymorphism. Carvedilol significantly increased the left ventricular ejection fraction, while decreasing the heart rate and malondialdehyde plasma concentrations in chronic heart failure patients with the Glu27 beta 2-adrenergic receptor allele. There were however, no significant changes in patients with the Gln27 beta 2-adrenergic receptor variant.</abstract><doi>10.1111/j.1742-7843.2008.00370.x</doi></addata></record>
fulltext fulltext
identifier ISSN: 1742-7835
ispartof Basic & clinical pharmacology & toxicology, 2009-05, Vol.104 (5), p.374-378
issn 1742-7835
1742-7843
language eng
recordid cdi_proquest_miscellaneous_20583303
source Wiley-Blackwell Read & Publish Collection
title Gln27 arrow right Glu beta 2-Adrenergic Receptor Polymorphism in Heart Failure Patients: Differential Clinical and Oxidative Response to Carvedilol
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T12%3A43%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gln27%20arrow%20right%20Glu%20beta%202-Adrenergic%20Receptor%20Polymorphism%20in%20Heart%20Failure%20Patients:%20Differential%20Clinical%20and%20Oxidative%20Response%20to%20Carvedilol&rft.jtitle=Basic%20&%20clinical%20pharmacology%20&%20toxicology&rft.au=Troncoso,%20Rodrigo&rft.date=2009-05-01&rft.volume=104&rft.issue=5&rft.spage=374&rft.epage=378&rft.pages=374-378&rft.issn=1742-7835&rft.eissn=1742-7843&rft_id=info:doi/10.1111/j.1742-7843.2008.00370.x&rft_dat=%3Cproquest%3E20583303%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-proquest_miscellaneous_205833033%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=20583303&rft_id=info:pmid/&rfr_iscdi=true